Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for commercialization of Tiotropium Dry Powder Inhaler (DPI), 18 mcg/capsule, in the Chinese market.
The agreement focuses on treating chronic obstructive pulmonary disease (COPD).
SUP will handle regulatory approvals for selling Tiotropium DPI in China.
Lupin will be the marketing authorization holder and responsible for manufacturing the product.
Fabrice Egros, President of Corporate Development, Lupin, stated that the partnership demonstrates their commitment to developing critical products for respiratory diseases and establishing leadership in the global respiratory health sector.
Wang Li, President of SUP, mentioned that the collaboration will strengthen their synergy in respiratory care and aim to make significant breakthroughs in respiratory disease treatment in China.